published meta-analysis   sensitivity analysis   studies

Immunostimulants drugs in infections other than COVID-19 - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathdetailed resultsHung, 2013 1.35 [0.29; 6.26] INSIGHT FLU-IVIG (Davey), 2019 1.18 [0.35; 3.94] IRC002 Study Team, 2017 0.20 [0.02; 1.74] IRC005 Study Team, 2019 0.77 [0.21; 2.86] 0.88[0.42; 1.81]Hung, 2013, INSIGHT FLU-IVIG (Davey), 2019, IRC002 Study Team, 2017, IRC005 Study Team, 201940%569moderatenot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-03-29 13:10 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 92 - treatments: 597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567 - roots T: 290